SAM J. SUGAR, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The conference on varicella zoster by Strauss and colleagues (1) may indeed reflect one viewpoint on using medications for treating zoster, but it certainly does not reflect current clinical practices.
Acyclovir, which is being marketed by its manufacturer (Zovirax, Burroughs Wellcome, Research Triangle Park, North Carolina) to be used extensively in primary care settings at the first evidence of an outbreak of zoster, appears to reduce the length of the illness from several weeks to several days when used in doses of 2 g per day for 5 days. In addition, the treatment of postherpetic neuralgia has
SUGAR SJ. Varicella-Zoster Virus Infection. Ann Intern Med. 1988;108:907. doi: https://doi.org/10.7326/0003-4819-108-6-907_2
Download citation file:
Published: Ann Intern Med. 1988;108(6):907.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use